🔬 La semana pasada, PROALT patrocinó en la @urjc el evento “Hacia la medicina de precisión en cáncer de colon”, con participación de Custodia García Jiménez, José Manuel González Sancho, Rocío Díaz Sánchez, Natalia Pendás Franco y nuestro CEO, Juan Ignacio Imbaud.
👉
96
🚀 Protein Alternatives will be be presenting at #BioTrinity2025 in Science Track 1!
📅 April 2 | 🕝 14:30-16:00
🔬 Science Spotlight Thirteen – New Platforms & Technologies for Drug Discovery
See you in London! ✨
#DrugDiscovery #Biotech #Innovation #ProteinAlternatives
14
Protein Alternatives joins DIVAVACEHD project to develop a vaccine against Epizootic Hemorrhagic Disease (EHD) in cattle
proteinalternatives.com/prot…
#ProteinAlternatives #Vaccines #Veterinary #EHD
12
Protein Alternatives Welcomes Dr Antoni Castells Garangou, MD, PhD, to our Scientific Advisory Board
proteinalternatives.com/prot…
#Welcome #Oncology #ProteinAlternatives
12
Protein Alternatives Welcomes Dr Alfredo Carrato Mena, MD, PhD, to our Scientific Advisory Board
proteinalternatives.com/prot…
#Welcome #Oncology #ProteinAlternatives
12
Protein Alternatives Welcomes Prof. Eric Van Cutsem, MD, PhD, to our Scientific Advisory Board
proteinalternatives.com/prot…
#Welcome #Oncology #ProteinAlternatives
12
Protein Alternatives welcomes back Hugo Cartagena in his new role as COO
proteinalternatives.com/prot…
#WelcomeBack #Biotechnology #ProteinAlternatives
16
Proalt will attend #biospain21 , which will take place at Pamplona from September 29th to October 1st
proteinalternatives.com/proa…
ProAlt was selected by the European Innovation Council (@EUeic) to participate in the EIC Corporate Day with Merck (@merckgroup)
Protein Alternatives announces the opening of new office in Boston proteinalternatives.com/prot…
Protein Alternatives retweeted
Patient-friendly presentations on a variety of topics related to #colorectalcancer are available from our virtual #Congress2020. Check out gccacongress.org. Did we mention it's 100% free? Enjoy the presentations and reach out to us with any ?s on socials [email protected]
A new study by @nature on the transmissibility of #SARSCOV2 states that 44% of #COVID19 infections occurred before the onset of symptoms
nature.com/articles/s41591-0…
Protein Alternatives retweeted
El proceso de validación de centros que colaboren en el diagnóstico con PCR continúa en el #ISCIII. Hay más laboratorios en fases avanzadas de capacitación que, tras garantizar requisitos de seguridad y recursos, podrían sumarse a corto plazo a los 13 centros ya validados. ⬇️
El @SaludISCIII ha validado la capacitación de 8 nuevos centros de investigación y universidades para que puedan realizar test de PCR.
Ya hay un total de 13 centros o universidades validados para la realización de pruebas de diagnóstico del #COVID19.
➡️https://teapawt.net/t.co/DiHHeF1FxB
According to public health researchers at Harvard University, the overall duration of SARS-CoV-2 epidemic could last into 2022, and we may need to maintain social distancing until 2022 and follow-up of infections until 2024. science.sciencemag.org/conte…
Los expertos reclaman una colaboración a nivel global para desarrollar la vacuna contra el coronavirus SARS-Cov-2
elpais.com/ciencia/2020-04-1… vía @el_pais
2
Protein Alternatives retweeted
Me he reunido con varias empresas biotecnológicas para abordar la producción de kits diagnósticos.
Tienen la experiencia en I+D para fabricarlos. Hemos conversado sobre cómo hacer más desarrollos, asegurar los suministros y cómo podría ayudar el Gobierno. https://teapawt.net/t.co/gysF4ncl0C
Protein Alternatives retweeted
Protein Alternatives retweeted
📢Announcing a new #CaixaImpulse Express Call for projects that address the #COVID19 pandemic.
🔹For projects or technologies focused on preventing, diagnosing, treating or monitoring this illness
🔹Selected projects will receive a grant of up to €300K
teapawt.net/cards/p0rk…
Protein Alternatives retweeted
La inmunoterapia previa a la cirugía puede hacer que el cáncer de colon se reduzca sustanciamente o desparezca
infosalus.com/farmacia/notic…
Protein Alternatives testará anticuerpos monoclonales frente al motivo RGD como un nuevo enfoque para el tratamiento de la COVID-19
linkedin.com/feed/update/urn…
#COVID19 #SARSCoV2 #coronavirus #Antibodies


















